Advanced GMP for ATMPs

11/12 June 2025, Vienna, Austria

Course No. 21883

header-image

Speakers

Dr Rainer Gnibl

Dr Rainer Gnibl

GMP Inspector

Dr. Sabine Hauck

Dr. Sabine Hauck

dequra pharma consult hauck, Chair of ECA ATMP Interest Group

Dr. Katja Aschermann

Dr. Katja Aschermann

TETEC

Dr. Wolfgang Schumacher

Dr. Wolfgang Schumacher

formerly F. Hoffmann-La Roche

Kati Kebbel

Kati Kebbel

Fraunhofer-Institut für Zelltherapie und Immunologie IZI

Mag. Gabriela Schallmeiner

Mag. Gabriela Schallmeiner

Inspection Ready Consulting, Austrian Qualified Person Association (aqpa)

Objectives

As part of this GMP course for ATMPs (Advanced Therapy Medicinal Products), you will learn about the existing regulatory requirements for aseptic manufacturing, CCS, data integrity, lyophilisation according to the new Annex 1 and much more from various experts from authorities, industry and consulting. In addition to the GMP requirements, you will also learn about the impact and implementation of the new Annex 1.

Background

The new Annex 1 is in effect and must now be implemented. The correct interpretation and implementation in daily business is often difficult and raises many questions. Compliance with the GMP regulations is essential for the continuous, traceable and high-quality manufacture, testing and control of pharmaceutical products.

Advanced Therapy Medicinal Products (ATMPs) are a group of innovative and sophisticated medical treatments that use advanced technologies to modify or use living cells, tissues or genes for therapeutic purposes. These therapies focus on targeting the underlying causes of disease at the cellular and genetic level, with the aim of treating, preventing or diagnosing diseases. ATMPs include gene therapies, cell therapies and tissue engineered products and represent a significant step in medical treatments.

New ATMPs with innovative properties are constantly being developed. It does not matter whether it is a personalized product, production or even transport. The ultimate goal always remains a safe and effective product that provides the patient with healing or relief without harming them. To ensure this, employees must comply with the current regulations. This course offers deeper insights into the regulations and advice on implementing the new and existing requirements of ATMPs.
 

Target Group

This training is aimed at employees from quality assurance, quality control and production who have daily contact with ATMPs and have to work according to the existing GMP requirements. Experienced staff will have the opportunity to extend and deepen their existing knowledge in core aspects of GMP and Annex 1 Areas.

Presentations/Certificate

The presentations for this event will be available for you to download and print before and after the event. Please note that no printed materials will be handed out on site and that there will not be any opportunity to print the presentations on site.

After the event, you will automatically receive your certificate of participation.

Programme

Advanced GMP for ATMPs

Seminar Programme as PDF

EU-GMP Guideline Part IV: Overview
Dr Rainer Gnibl
  •  Positioning within EudraLex Vol. 4
  •  Definition of ATMPs
  •  Document structure & technical content
  •  Key messages
Quality Risk Management for ATMPs
Dr Rainer Gnibl
  •  What does QRM mean?
  •  ICH Q9 Quality Risk Management (Overview)
  •  Bounderies & Limitations
  •  Examples from Guideline
Freeze-drying of Vectors in the Light of Update Annex 1
Dr Sabine Hauck
  •  Annex 1 requirements for lyophilization
  •  Further regulatory requirements for (non-)viral vectors
  •  Benefits of freeze-dried viral vector formulations
Aseptic Manufacturing of Cell-based ATMPs (HCGTP)
Dr Katja Aschermann
  •  Challenges
  •  Impact of new Annex 1
  •  Cross Contamination Control Strategy
Environmental Monitoring
Dr Rainer Gnibl
  •  Segregation between Classification, Qualification & Monitoring
  •  Clean room lifecycle
  •  Monitoring elements
  •  Personell & clean room monitoring
Data Integrity of Automated, Decentralised Cell Therapy Production
Dr Wolfgang Schumacher
  •  DI concept in research-oriented smaller companies
  •  Computer-assisted manufacturing of therapeutics
  •  DI issues in testing, release and logistics 
  •  DI questions in the context of inspections
Contamination Control Strategy
Dr Katja Aschermann
  •  Definition
  •  Creation of a CCS
  •  Selected items
Qualification and Validation – a Versatile and Efficient Quality Tool in the ATMP Manufacturing
Kati Kebbel
  • Clarification of types of qualification and validation applied in ATMP manufacturing
    - supplier qualification
    - device qualification
    - software validation
  •  (Aseptic) process qualification / Validation
    - method Validation
    - operator qualification
  • Regulatory basis
  • How are these types used in the ATMP manufacturing - described in a case study for a clinical phase I/II ATMP
ATMPs a Challenge for Quality Control
Dr Katja Aschermann
  • From product to control strategy via CQAs
  • Measurement of quality attributes
  • Specifications
  • Stability
  • Validation
Regulatory Landscape - Opportunities and Challenges
Gabriela Schallmeiner
  • Overview for ATMPs
  • Specific requirements for ATMPs - opportunities and challenges
  • Examples on points to consider in CMC
If the Guidelines become a Challenge
Kati Kebbel
  • Media Growth Promotion Test according to EP 2.6.1 vs. 2.6.27 and impact to sterility method validation
  • APS challenges
  • Change of standard APS strategy - a future Vision?
Batch Release - What to Consider for AT(I)MPs
Gabriela Schallmeiner
  •  EU Regulatory framework
  •  GMP for AT(I)MPs
  •  QP batch certifcation

stop

This course is part of the GMP Certification Programme "ECA Certified Biotech Manager" Learn more

ECA-Member*: € 1690,-
Non ECA Member*: € 1890,-
EU/GMP Inspectorates*: € 945,-
APIC Member Discount*: € 1790,-

(All prices excl. VAT). Important notes on sales tax.

* also payable by credit card
American Express Visa Mastercard

icon
Further dates on-site
Further dates on-site
Not available
icon
Further dates online
Further dates online
Not available
icon
Recording
Not available

Do you have any questions?

Please contact us:
Tel.: +49 6221 8444-0
E-Mail: info@gmp-compliance.org

Woman with headset

Go back

Testimonials about our courses and conferences

"Great material and speakers" and "Great speakers a lot of experience and sharing"

Felipe Gonzalez, Mucos Emulsionsgesellschaft mbH
Live Online Training - Granulation & Tableting, September 2024

"Nice presentations: easy understanding, quite visual"

Susana Manrique, Boehringer Ingelheim España, S.A,
Live Online Training - Granulation & Tableting, September 2024

“Fantastic course – I really enjoyed the interactive structure & greatly appreciate social activity.”

Anthony Cummins, Sebela Pharmaceuticals, Ireland
GMP Auditor Practice, September 2023

 

“Very well organized, information on point without being overwhelming.”

Eleni Kallinikou, Pharmathen
Live Online Trainng - Pharmaceutical Contracts - Febuary 2024

 

“Good overview of different types of agreements, good to see both the GMP and the legal angle”

Ann Michiels, Johnson&Johnson
Live Online Trainng - Pharmaceutical Contracts, Febuary 2024

 

 

“Well prepared presentations and good presenters. I also like the way of asking questions.”

Alexandra Weidler, Hookipa Biotech GmbH, Austria
Live Online Training – QP Education Course Module A, November 2023